AMENDMENTS
854 - 1183

Draft report
Véronique Trillet-Lenoir
(PE693.752v01-00)

on Strengthening Europe in the fight against cancer - towards a comprehensive and coordinated strategy
(2020/2267(INI))
Amendment 854
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 53 a (new)

Motion for a resolution

53a. Stresses the need for all patients to have a right of access to specific treatments for the sequelae of cancer or cancer treatment, allowing them to regain maximum autonomy and quality of life, such as cognitive rehabilitation in brain tumours, voice rehabilitation in patients with laryngectomies, physical rehabilitation in the case of immobilisation or muscle damage, prostheses in cases of upper or lower limb amputations due to osteosarcoma, treatment of lymphedema in patients who have undergone lymphadenectomy, breast reconstruction treatment, and aesthetic treatments in cases of skin lesions;

Or. en

Amendment 855
Sunčana Glavak

Motion for a resolution
Paragraph 53 b (new)

Motion for a resolution

53b. Insists that both public and private institutions that meet the quality assurance criteria should be included in national cancer control plans as part of Europe’s Beating Cancer Plan with the goal of providing the highest level of cancer treatment quality to all patients across the EU;

Or. en
Amendment 856
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 53 c (new)

Motion for a resolution 53c. Considers it necessary to facilitate access to services for people with disabilities by eliminating structural and transport barriers, as well as the equipment itself, designed for non-disabled people;

Amendment 857
Peter Liese, Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 53 d (new)

Motion for a resolution 53d. Stresses the importance of standardized surgical oncology treatments to improve long term quality of life of cancer survivors;

Amendment 858
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 53 e (new)

Motion for a resolution 53e. Stresses the importance of
Amendment 859
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 54

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;
Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; considers that, when developing this EU network, the Commission should consider the need to invest in state-of-the-art equipment and recommends that a diversity of well-trained cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, nuclear medicine, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients;
Motion for a resolution
Paragraph 54

Amendment 861
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; considers that, within the plan, reference centres for paediatric cancers should be linked together and coordinated in a paediatric reference centres area; recommends that a diversity of cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients; calls on the Commission and the Member States to support the sustainability of pre-existing cross-border collaborations;

Or. en

Amendment 862
Hilde Vautmans, Irena Joveva, Alin Mituța
54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; considers that, within this Plan, reference centres for paediatric cancers should be linked and coordinated in a paediatric reference centres area; recommends the establishment of core objectives for the new Network of centres as an early task; stresses that these objectives should include the reduction of inequalities, strengthening of translational, clinical and outcomes research, and integration of clinical care and research;

Amendment 863
Margarita de la Pisa Carrión

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;
Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; recommends that a diversity of cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients;

Amendment 864
Alexis Georgoulis

Motion for a resolution
Paragraph 54

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment
54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;
Motion for a resolution

Paragraph 54

Motion for a resolution

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; recommends the establishment of core objectives for the new Network of centres as an early task; stresses that these objectives should include the reduction of inequalities, strengthening of translational, clinical and outcomes research, and integration of clinical care and research;

Or. en

Amendment 865
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; calls on the European Commission and the Member States to support the sustainability of pre-existing cross-border collaborations, such as in the paediatric cancer sector, and the European Reference Networks; recommends the implementation and enforcement of multi-disciplinary collaboration the soonest possible to improve the quality of care for patients; considers that cancer specialties and medical disciplines should
**Amendment 866**
Maria Spyraki

**Motion for a resolution**
**Paragraph 54**

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

**Amendment**

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU, and to support the already existing European Reference Networks (ERNs) as well as the development of guidelines and quality assurance schemes for cancer types (e.g. blood cancers) that will not be covered by the Knowledge Center for Cancer; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

**Amendment 867**
Vlad Gheorghe

**Motion for a resolution**
**Paragraph 54**
54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; calls also on the Commission to support Member States by earmarking some of the budget in the cohesion and regional funds to support the establishment of these centres to ensure full coverage of the population;
the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

calls on the Commission and the Member States to support the sustainability of pre-existing cross-border collaborations, such as in the paediatric cancer sector, and the European Reference Networks;

Amendment 869
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolores Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arlukowicz, Christian Sagartz

Motion for a resolution
Paragraph 54

Motion for a resolution

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;
Amendment 870
Joëlle Mélin

Motion for a resolution
Paragraph 54

Motion for a resolution

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; calls for this network to also be used to harmonise approaches to screening for common comorbidities of cancer;

Or. fr

Amendment 871
Ivars Ijabs, Alin Mituţa, Irena Joveva, Hilde Vautmans, Nicolae Ştefănuţă

Motion for a resolution
Paragraph 54

Motion for a resolution

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; calls for this network to also be used to harmonise approaches to screening for common comorbidities of cancer;
centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment 872
Bartosz Arłukowicz

Motion for a resolution
Paragraph 54

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;
Amendment 873
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 54

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Amendment

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, *anticipatory and responsive* research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Or. en

Amendment 874
Pietro Fiocchi

Motion for a resolution
Paragraph 54

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote

Amendment

54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote
the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute;

Or. en

Amendment 875
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 55

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

Amendment

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Institute in charge of the implementation and follow-up of the respective National Cancer Strategy (NCS); stresses that, for this purpose, clear objectives should be set accompanied by adequate resources and management; recommends that the NCSs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the Association of European Cancer Institutes;

Or. en

Amendment 876
Pietro Fiocchi

Motion for a resolution
Paragraph 55

55. Calls for the identification,

Amendment

55. Calls for the identification,
reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;
these organisations coordinated by the European Cancer Institute;

Or. en

Amendment 878
Loucas Fourlas

Motion for a resolution
Paragraph 55

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; calls for the inclusion of a dedicated paediatric cancer component in all NCCPs to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients;

Or. en

Amendment 879
Vlad Gheorghe

Motion for a resolution
Paragraph 55
55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; stresses that a NCCP should include provisions on adequate staff capacities so as to guarantee sufficient number of oncology medical workers in each Member State, commensurate with the overall population number;

Amendment 880
Bronis Ropé

Motion for a resolution
Paragraph 55

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; calls for the NCCPs’ contents to resemble as closely as
European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

possible Europe's Beating Cancer Plan in order to facilitate the latter's successful implementation; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

Or. It

Amendment 881
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 55

Motion for a resolution

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

Amendment

55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), in coherence with WHO guidance on NCCPs, consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute;

Or. en
Amendment 882
Bronis Ropé

Motion for a resolution
Paragraph 55 a (new)

Motion for a resolution

Amendment

55a. Strongly encourages the drive to improve cancer control standards in EU countries by entrusting oversight over NCCPs to the unique structures of the National Cancer Institutes; stresses that, since the services provided by these institutions as centres of excellence are more efficient due to the integration of scientific and clinical activities and the rapid implementation of scientific innovations, a network of national cancer centres of excellence must be created and developed within and between EU Member States, from which at least 90% of cancer patients would obtain services; stresses that the full functioning of these unique scientific and medical institutions in the field of oncology depends on the development of an appropriate legal framework and on ensuring the financial stability of these institutions;

Or. lt

Amendment 883
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 55 b (new)

Motion for a resolution

Amendment

55b. Highlights the importance of personalised medicine in identifying the best treatment option for each patient throughout their illness; points out that this approach delivers better results,
reduces the risk of side effects in patients suffering from cancer, and also cuts costs while improving the effectiveness of healthcare systems;

Amendment 884
Michèle Rivasi

Motion for a resolution
Paragraph 55 c (new)

Motion for a resolution

Amendment

55c. Calls on Member States to integrate the specificities of rare cancers in adults as well as paediatric cancers in distinct sections in all the NCCPs; calls on the Commission to coordinate the creation of national networks for rare adult cancers and develop mechanisms to better integrate European Reference Networks (ERNs) in their respective national healthcare systems;

Amendment 885
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 55 d (new)

Motion for a resolution

Amendment

55d. Calls for the inclusion of a dedicated paediatric cancer component in all National Cancer Strategies (NCSs) to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients;
Amendment 886
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 55 e (new)

Amendment

55e. Calls on the Commission and EU Member States to provide early access to new forms of therapy and surgery through the NCCP, including treatments accompanied by molecular diagnostics, robot surgery and radiation therapy;

Or. en

Amendment 887
Joëlle Mélin

Motion for a resolution
Paragraph 55 f (new)

Amendment

55f. Calls for the most holistic approach possible towards patients which considers their overall physical and mental health, including their diet and the potential consequences of polymedication; suggests, to this end, that the oncology team and practitioner attending to a patient remain in constant contact before, during and after treatment;

Or. fr

Amendment 888
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Subheading III.B
Motion for a resolution

III.B. Equal access to cancer care: towards a European Medicines Market

Amendment

III.B. Equal access to cancer care

Or. pt

Amendment 889
Joëlle Mélin

Motion for a resolution

Subheading III.b

Motion for a resolution

III.b Equal access to cancer care: towards a European Medicines Market

Amendment

III.b Equal access to cancer care

Or. fr

Amendment 890
Michèle Rivasi

Motion for a resolution

Subheading III.b

Motion for a resolution

III.b Equal access to cancer care: towards a European Medicines Market

Amendment

III.b Equal access to cancer care: towards equal access to medicines in Europe

Or. en

Amendment 891
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz
Motion for a resolution
Subheading III.b

Motion for a resolution

III.b Equal access to cancer care: towards a European Medicines Market

Amendment

III.b Equal access to cancer care and treatment in all Member states: towards a European Medicines Market

Or. en

Amendment 892
Michèle Rivasi

Motion for a resolution
Paragraph 56

Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European regulatory environment in order to guarantee equal access to adequate treatment options, including medicines, surgery and radiotherapy, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve efficacy and safety of cancer treatments for adults and children;

Or. en

Amendment 893
Kateřina Konečná, Alexis Georgoulis

Motion for a resolution
Paragraph 56

Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for

Amendment

56. Calls on the Commission and antitrust authorities to assess and defend the European medicines market keeping the attention on the acquisition of SMEs by large pharmaceutical companies that
innovative treatments, and improve cancer treatments for adults and children;

undermine fair competition;

Amendment 894
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 56

Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to develop a plan of collaboration between Member States in order to improve the functioning of the European medicines market so as to guarantee equal access and availability to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment 895
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 56

Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to evaluate and form the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, improve cancer treatments for adults and children, and thus ensuring health as a human right and a public good for all;
Amendment 896
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Špyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 56

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

56. Calls on the Commission to strengthen the European medicines market in order to improve equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; 

encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives;

Or. en

Amendment 897
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 56

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

encourages a multi-stakeholder dialogue
on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives; considers, in this respect, that market access for nuclear medicine applications should be harmonised across all Member States;

Amendment 898
Loucas Fourlas

Motion for a resolution
Paragraph 56

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives;

Amendment 899
Tudor Ciuhodaru

Motion for a resolution
Paragraph 56

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives;
Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

considers, in this respect, that market access for nuclear medicine applications should be harmonised across all Member States;

Or. en

Amendment 900
Bartosz Arłukowicz

Motion for a resolution
Paragraph 56

Motion for a resolution

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to innovative treatment, including personalised medicine, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Or. pl

Amendment 901
Pietro Fiocchi

Motion for a resolution
Paragraph 56
56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, encourage the use of generic and biosimilar medicines and improve cancer treatments for adults and children;

Or. en

Amendment 902
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 56

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children;

Amendment

56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative技术和treatments, and improve cancer treatments for adults and children;

Or. en

Amendment 903
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 56 a (new)

56a. Calls on the Member States to step up national research and production capacity for medicines and other health
products, including by establishing national medicines laboratories, with a view to providing equal access to treatment, reducing medicines shortages and dependence on the pharmaceutical industry, securing cost-free access to innovative treatments and improving cancer treatments for adults and children; calls on the Member States, further, to provide cost-free access to treatments and medicines used by cancer patients by means of their public health services and to consider medicine policies that provide cost-free access to medicine for users over the age of 65, the chronically ill and families in economic need;

Amendment 904
Michèle Rivasi

Motion for a resolution
Paragraph 56 b (new)

Motion for a resolution  Amendment

56b. Calls for strengthening the EU medicine marketing authorisation framework and evidentiary requirements on medicine safety and efficacy; highlights the importance of randomised controlled clinical trials that compare an investigational pharmaceutical product against standard treatment for evidence on its added value; calls for generating evidence on the efficacy of cancer medicines based on clinically relevant endpoints; calls for clinical trials to be adequately representative of the patient population;

Or. en
Amendment 905  
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes  

Motion for a resolution  
Paragraph 56 c (new)  

Motion for a resolution  

Amendment  
56c. Calls on the Commission to discourage practices which extend market exclusivity, prolong intellectual property protection and lead to profit maximization, through strategic use of intellectual property rights, such as incremental patenting of existing products ("ever-greening" strategies), and to promote generic competition for off-patent rare disease drugs;  

Or. en  

Amendment 906  
Michèle Rivasi  

Motion for a resolution  
Paragraph 57  

Motion for a resolution  

Amendment  
57. Calls on the Commission to introduce in its Pharmaceutical Strategy a revision of Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use27; and  

Regulation (EC) No 726/2004 to strengthen the marketing authorisation framework, improve medicine availability and increase generic and biosimilar competition;  


Or. en
Amendment 907
Tudor Ciuhodaru

Motion for a resolution
Paragraph 57


--------------------------

Amendment

57. Calls on the Commission to introduce in its Pharmaceutical Strategy a revision of Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use; considers that, while recognising nuclear medicine as one of the most efficient ways to tackle the disease, the revision of the Directive 2001/83/EC should recognise the particularities of nuclear medicine by addressing the challenges currently limiting the further deployment of innovation in the sector;

--------------------------

Amendment 908
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

--------------------------

58. Notes that cancer patients are frequently affected by medicine shortages or high medicine costs; calls on the Commission and the Member States to work together to counter shortages of all medicines and medical products in every country and of cancer medicines in particular, which will require every state to build their research, development and production capacity for medicines and other medical products, thus safeguarding
their national sovereignty in this area; considers that any development of a common basket of the cancer drugs, within the framework of cooperation among Member States, of which there may be shortages to ensure that patients have continuous access to appropriate treatment must not undermine the autonomy or sovereignty of every Member State in their consolidation of their own reserve in line with their needs and interests or their development of capacity in the production of medicines and other medical products;

Or. pt

Amendment 909
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 58

Motion for a resolution

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Amendment

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy to improve collaboration between Member States in order to manage and prevent shortages of all essential medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Or. en

Amendment 910
Michèle Rivasi

Motion for a resolution
Paragraph 58
58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for preventing and managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of critical cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Amendment 911
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for preventing and managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of critical cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

underlines specifically the fundamental issues posed by the shortage of paediatric medicines; underscores that Articles 24 and 35 of the EU Charter of Fundamental rights and Article 168 of TEU prescribe that children have the right to a high level of human health protection and to care, as is necessary for their wellbeing, as well as to high quality and safe medicines; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Or. en
Amendment 912
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Amendment

58. Notes that cancer patients are frequently affected by medicine shortages and that severe disruptions in the supply of cancer treatments are highly detrimental for cancer patients, carers and families; calls on the Commission to develop a clear and harmonised definition as well as detailed and transparent requirements and to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Or. en

Amendment 913
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of

Amendment

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular, including shortages of inexpensive essential cancer medicines;
which there may be shortages to ensure that patients have continuous access to appropriate treatment;
supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; *highlights also the enormous problems posed by medicines shortages in paediatrics from an ethical and fundamental rights perspective;*

Amendment 914
Alessandra Moretti

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Amendment 58
58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular, including shortages of inexpensive essential cancer medicines; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;

Amendment 915
Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen

Motion for a resolution
Paragraph 58

58. Notes that cancer patients are frequently affected by medicine shortages;
calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;
Motion for a resolution

58a. Calls on the Commission to include in the EU Statistics on Income and Living Conditions (EU-SILC) data on self-reported unmet needs regarding access to cancer medicines, as so far access to medicines, including cancer medicines, is not measured in the EU-SILC, and to start the development of a common basket of the cancer drugs that risk shortages from the data collected in the EU-SILC;

Or. en

Amendment 918
Bronis Ropė

Motion for a resolution
Paragraph 58 b (new)

58b. Points out that, in order to ensure equal access to treatment, reduce shortages in innovative medicines and reduce disparities in the price of medicines, it is essential that uniform quality protocols for the diagnosis and treatment of oncological diseases, which should be regularly updated with the involvement of professional organisations, be established and applied as a matter of priority in the Member States;

Or. lt

Amendment 919
Bronis Ropė

Motion for a resolution
Paragraph 58 c (new)
58c. Deplores the existing differences in the reimbursement systems for cancer medicines in the Member States and proposes that vital and binding lists of essential cancer medicines be established in a harmonised way, at EU level, so that cancer patients in the Member States will have the right to reimbursement by the national health insurance funds in a harmonised manner in all the Member States;

Or. lt

Amendment 920
Bronis Ropé

Motion for a resolution
Paragraph 58 d (new)

58d. Stresses that the availability of innovative medicines cannot be limited by bureaucratic reimbursement mechanisms; calls not only for the joint evaluation of medical technologies and medicines, but also for all medicines registered by the European Medicines Agency (EMA) and technologies recognised in the EU to be automatically registered in all EU countries without additional bureaucratic screening mechanisms; considers that the availability of medicines and technologies can only be limited by a country's economic resources and that this should be addressed by making cancer treatment a priority area for European and national health systems;

Or. lt
Amendment 921
Michèle Rivasi

Motion for a resolution
Paragraph 59

Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement, diversification and increased transparency of the medicines supply chain within the EU, close monitoring of medicine supply chains, tensions and shortages; calls for the EU pharmaceutical legislation to introduce a legal obligation for pharmaceutical companies to maintain adequate safety stocks and the creation of a strategic stockpile of critical medicines, active ingredients or raw materials, particularly where the number of suppliers is limited;

Or. en

Amendment 922
Alessandra Moretti

Motion for a resolution
Paragraph 59

Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement and diversification of the supply, in particular that of cancer drugs, within the EU, close monitoring of supply tensions and shortages, and the creation of a European stockpile of such medicines;

Or. en

Amendment 923
Tomislav Sokol, Sunčana Glavak
Motion for a resolution
Paragraph 59

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages at EU level, and the creation of a strategic stockpile of such medicines; urges the Commission, in the context of the EU Public Procurement Directive 2014/24/EU, to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs, in particular with regard to the implementation of the criteria of the most economically advantageous tender (MEAT), aimed at ensuring long-term sustainability, competition and security of supply and stimulating investment in manufacturing; calls for remedies against single-winner, price-only tenders that can cause severe price erosion, reducing the number of suppliers on the market and often resulting in short lead times and penalties being applied to companies, which in turn increases the risk of shortages of medical products; calls, in this respect, for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;

Amendment 924
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 59
59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

urges the Commission, in the context of the EU Public Procurement Directive 2014/24/EU, to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs, in particular with regard to the implementation of the criteria of the most economically advantageous tender (MEAT), aimed at ensuring long-term sustainability, competition and security of supply and stimulating investment in manufacturing;

Or. en

Amendment 925
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estarás Ferragut, Francisco José Millán Mon, Nathalie Colin-Oesterlé, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Antonio López-Istúriz White, Adrián Vázquez Lázar, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 59

Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;
not relying exclusively or prominently on the criterion of price, in order to foster the sustainability of the supply chain and the resilience of the national health systems, and to avoid a delocalization aimed at reducing the costs of manufacturing;

Amendment 926
Nicolás González Casares, María Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 59

Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; stresses the importance of the role of sustainable procurement practices in preventing medicine shortages; calls on the Commission to support Member States in the prevention of shortages by developing EU guidelines on procurement of medicines, aimed at ensuring long-term sustainability, competition, security of supply and stimulating investments in manufacturing;

Amendment 927
Tudor Ciuhodaru

Motion for a resolution
Paragraph 59
Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; calls, in this respect, for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;

Amendment 928
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 59

Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, the strengthening of stocks' transparency at a national level, the establishment of an alert system notifying the growing risks of shortages, and the creation of a strategic stockpile of such medicines;

Amendment 929
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 59
Motion for a resolution

59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment

59. Calls for the reinforcement and diversification of the Member States’ supply chain, in particular that of cancer drugs, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines;

Amendment 930
Pietro Fiocchi

Motion for a resolution
Paragraph 59 a (new)

Motion for a resolution

59a. Stresses the importance of the role of sustainable procurement practices in preventing medicine shortages; recalls that, as recognised in the EU industrial strategy, public procurement can lead to market consolidation and increase the risk of shortages; calls on the Commission to support Member States in the prevention of shortages by developing EU rules on procurement of medicines, under the current public procurement directive, aimed at ensuring long-term sustainability, competition, security of supply and stimulating investments in manufacturing; considers that these targeted guidelines should cover clarifications and recommendations to Member States on how to implement multi-winner framework agreements, apply Most Economically Advantageous Tender (MEAT) criteria, recognise investments in security of supply for Europe, as well as ensure timely procurement processes to promote the plurality of manufacturers and competition of multi-source medicines as
soon as they are available;

Amendment 931
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 59 b (new)

59b. Recalls that just-in-time drug production increases the risk of shortages; calls on Member States to implement shortage management plans, including binding pharmaceutical industries to constitute a security reserve in order to better prevent cancer drugs stock shortages;

Amendment 932
Joëlle Mélin

Motion for a resolution
Paragraph 60

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;

Amendment 933
Alessandra Moretti
60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;

Amendment

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines and other healthcare products and services for patients; calls for the introduction of a strategic objective in the Europe's Beating Cancer Plan as well as in the national cancer strategies to actively promote the use of off-patent medicines, where appropriate and beneficial for the patients; stresses that their market entry should not be hampered or delayed and calls for the entry to market at the day 1 after IP expires to provide life-saving oncological generic and biosimilar medicines to patients;

Or. en

Amendment 934
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 60

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;

Amendment

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines and other healthcare products and services for patients; calls for the introduction of a strategic objective in the Europe's Beating Cancer Plan as well as in the national cancer strategies to actively promote the use of off-patent medicines, where appropriate and beneficial for the patients; stresses that their market entry should not be hampered or delayed and calls for the entry to market at the day 1 after IP expires to provide life-saving oncological generic and biosimilar medicines to patients;
medicines, where appropriate and beneficial for patients; stresses that their market entry should not be hampered or delayed and their development process should be promoted and funded;

Amendment 935
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 60

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;

Amendment
60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed because of unfair business strategies; urges for removing barriers to uptake and foster biosimilar medicines competition by designing policies that create a healthy long-term competition and promote biosimilar medicines use in the EU and National Cancer Strategies to ignite competition;

Amendment 936
Michèle Rivasi

Motion for a resolution
Paragraph 60

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and

Amendment
60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and
savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; calls on the Commission to increase resources to address anti-competitive and abusive market practices, including extension of market exclusivity and intellectual property protection, excessive pricing and pay-for-delay deals leading to competition distortion and profit maximisation;

Amendment 937
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 60

Motion for a resolution

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;

Amendment

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; calls on the Commission to address the misuse of the IPR (industrial property rights) system to delay market entry of generic and biosimilar medicines;

Amendment 938
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 60

Motion for a resolution

60. Points out that generic and

Amendment

60. Points out that generic and
biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; provided that intellectual property rights are respected; 

Amendment 939
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 60

Motion for a resolution

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; 

Amendment

60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition, innovation and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; 

Amendment 940
Joëlle Mélin

Motion for a resolution
Paragraph 61

Motion for a resolution

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June

Amendment

deleted

PE697.581v01-00 52/187 AM\1239353EN.docx
to support harmonised access to innovative cancer diagnosis and treatments;


Amendment 941
João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 61

Motion for a resolution

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021 to support harmonised access to innovative cancer diagnosis and treatments;


Amendment 942
Alessandra Moretti

Motion for a resolution
Paragraph 61

61. Considers that Member States should converge on the evaluation of medical technologies to support access to innovative cancer diagnosis and treatments;

Or. fr

Or. pt
61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^28\) to support harmonised access to innovative cancer diagnosis and treatments; supports cancer medicines being used as a pilot to jointly assess medicines under the Health Technology Assessment (HTA) regulation; calls on the Commission and Member States to take further measures aimed at encouraging the uptake and use of Joint Clinical Assessments that are to be carried out under the regulation; highlights the existence of tools being used by the World Health Organization (WHO) to incorporate cancer medicines on the WHO Model List of Essential Medicines;


Amendment 943
Nicolás González Casares, María Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 61

\textit{Motion for a resolution}  

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^28\) to support harmonised access to innovative cancer diagnosis and treatments; supports cancer medicines being used as a pilot to jointly assess medicines under the Health Technology Assessment (HTA) regulation; calls on the Commission and Member States to take further measures aimed at encouraging the uptake and use of Joint Clinical Assessments that are to be carried out under the regulation; highlights the existence of tools being used by the World Health Organization (WHO) to incorporate cancer medicines on the WHO Model List of Essential Medicines;

Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\textsuperscript{28} to support harmonised access to innovative cancer diagnosis and treatments; supports cancer medicines being used as a pilot to jointly assess medicines under the Health Technology Assessment (HTA) regulation; calls on the Commission and Member States to take further measures aimed at encouraging the uptake and use of Joint Clinical Assessments that are to be carried out under the regulation; highlights the existence of tools being used by the World Health Organization (WHO) to incorporate cancer medicines on the WHO Model List of Essential Medicines;


Amendment 944
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 61

\emph{Motion for a resolution}

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\textsuperscript{28} to support harmonised access to innovative cancer diagnosis and treatments; encourages more equitable access to medicines for patients across Europe by increasing the quality and efficiency of decision-making


Or. en
process; calls on Member States to intensify the close European cooperation on joint clinical assessments to use HTA resources more effectively after the pandemic and create a viable framework;

Amendment 945
Michèle Rivasi

Motion for a resolution
Paragraph 61

Motion for a resolution

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021 to support harmonised access to innovative cancer diagnosis and treatments;

Amendment

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021 to support harmonised assessment of and access to innovative cancer diagnosis and treatments; calls for enhanced collaboration between HTA authorities and developers on the design of clinical trials;


Or. en
Amendment 946
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 61

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^ {28}\) to support harmonised access to innovative cancer diagnosis and treatments;


Amendment

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^ {28}\) to support harmonised access to innovative cancer diagnosis and treatments; \textit{calls for the mandatory involvement of HTA experts in the design of clinical trials used for marketing authorization application;}


Or. en

Amendment 947
Søren Gade

Motion for a resolution
Paragraph 61

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^ {28}\) to support harmonised access to innovative cancer diagnosis and treatments;


Motion for a resolution

61. Considers that Member States should converge on \textit{evidence-based scientific} evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\(^ {28}\) to support harmonised access to innovative cancer diagnosis and treatments;
Amendment 948
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 61

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021 to support harmonised access to innovative cancer diagnosis and treatments;

Amendment

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021 to support harmonised and faster access to innovative cancer diagnosis and treatments;

Amendment 949
Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen

Motion for a resolution
Paragraph 61

61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore,
the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021\textsuperscript{28} to support harmonised access to innovative cancer diagnosis and treatments;


---

Amendment 950
Bronis Ropé

Motion for a resolution
Paragraph 61 a (new)

\textit{Motion for a resolution}

\texttt{61a. Points out that the comprehensive assessment of health technologies requires significant financial resources and is therefore often difficult to implement in the smaller Member States, which leads to inequalities in health care between Member States; calls for the promotion of cooperation between Member States in the joint assessment of medical technologies, with a view to eventually eliminating existing disparities in capacity in this field;}

\texttt{Or. It}

Amendment 951
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 61 a (new)
61a. Considers that lessons learnt from the COVID-19 pandemic, like the use of rolling review for promising medicine during public health emergencies should also be used for promising oncological medicine in order to accelerate the timely approval of innovative cancer therapies, reducing delays and speeding up access to potential lifesaving treatments for patient;

Or. en

Amendment 952
Joëlle Mélin

Motion for a resolution
Paragraph 62

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Or. fr

Amendment 953
Maria Arena

Motion for a resolution
Paragraph 62
62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

62. Recalls that all patients have the right to optimal treatment, regardless of their financial means, gender, age or nationality; notes with concern that there is a great disparity in the availability of and access to different cancer therapies, with unaffordability being one of the main reasons; insists therefore on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; calls on the Commission to make fair pricing and affordability of new treatments a core element of the Europe’s Beating Cancer Plan and the Pharmaceutical Strategy for Europe, notably by attaching conditionalities to both national and European public funding (e.g., Horizon Europe, Innovative Medicines Initiative - IMI) and ensure that public investment in R&D is accounted for and that medicines resulting from publicly funded research are available for a fair and affordable price; calls for more transparency throughout the pharmaceutical system, especially regarding pricing components, reimbursement criteria and the actual (net) prices of medicines in different European countries to ensure fairer prices and bring public accountability in the pharmaceutical sector;

Or. en

Amendment 954
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 62
Motion for a resolution

62. Insists on the need to ensure equal access to **affordable** drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that **pharmaceutical companies** should **respect** conditionalities on **charging an affordable price for** medicines developed in the framework of publicly funded research;

Amendment

62. Insists on the need to ensure **affordable prices and equal access to** drugs, in particular cancer drugs, within the EU, **to avoid patients having their treatments delayed or incomplete**; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that **relevant public authorities** should **introduce** conditionalities related to affordability, **availability and access to** medicines developed in the framework of publicly funded research; **underlines that this should also be the case for medicines benefiting from specific regulatory or market protection such as medicines developed to treat rare or paediatric cancers**;

Or. en

Amendment 955
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 62

Motion for a resolution

62. **Insists on** the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; **calls for** collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; **considers that** **pharmaceutical companies should respect** conditionalities on **charging an affordable price for** medicines developed in the framework of publicly funded research;

Amendment

62. **Acknowledges** the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; **points out the possibility for Member States to engage in voluntary** collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; **highlights the vastly different conditions, national healthcare and reimbursement systems, patient profiles, infrastructure capacities and financial burdens of**
Member States as some of the main factors dictating the pricing of medicines;

Or. en

Amendment 956
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyrači, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 62

Motion for a resolution

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Amendment

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls on Member States to consider joint price negotiation with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Or. en

Amendment 957
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 62

Motion for a resolution

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries,

Amendment

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for voluntary collective negotiation on the price of medicines with pharmaceutical
as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Amendment 958
Tudor Ciuhodaru

Motion for a resolution
Paragraph 62

Motion for a resolution

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Or. ro

Amendment 959
Michèle Rivasi

Motion for a resolution
Paragraph 62

Motion for a resolution

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration, including the setting of price ceilings; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Or. ro

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration, including the setting of price ceilings; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;
collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Amendment 960
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 62

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; anticipatory and responsive research;

Amendment

62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded anticipatory and responsive research;

Amendment 961
Pietro Fiocchi

Motion for a resolution
Paragraph 62

AM\1239353EN.docx 65/187  PE697.581v01-00
62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;

Or. en

Amendment 962
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 62

62. Insists on the need to ensure equal access to safe, effective and affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in particular with the support of public funding;

Or. en

Amendment 963
Hilde Vautmans, Irena Joveva
Motion for a resolution
Paragraph 62 a (new)

Motion for a resolution

Amendment

62a. Calls on the Commission and Member states to use HTA in reimbursement decisions and to promote innovative reimbursement schemes among Member States;

Or. en

Amendment 964
Joëlle Mélin

Motion for a resolution
Paragraph 63

Motion for a resolution

Amendment

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

Or. fr

Amendment 965
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arługowicz, Christian Sagartz

Motion for a resolution
Paragraph 63

Motion for a resolution

Amendment

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

AM\1239353EN.docx 67/187 PE697.581v01-00
improve affordability and access to cancer treatments at EU level; **highlights that joint public procurement should not hinder patient access, medical innovation or competition;**

<table>
<thead>
<tr>
<th>Amendment 966</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cereda, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</td>
</tr>
</tbody>
</table>

Motion for a resolution
Paragraph 63

<table>
<thead>
<tr>
<th>Motion for a resolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>63. Strongly advocates the extension of joint procurement procedures for diagnostics procedures as well as companion diagnostic tests and cancer medicines to improve affordability and access to cancer treatments at EU level; considers that special attention to paediatric and rare cancers should be given in this regard;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Or. en</th>
</tr>
</thead>
</table>

Amendment 967
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 63

<table>
<thead>
<tr>
<th>Motion for a resolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>63. Strongly advocates the extension of joint procurement procedures for cancer medicines, especially in times of health crises, to counter shortages and improve affordability and access to cancer treatments at EU level; notes that the procedures should improve response times</td>
</tr>
</tbody>
</table>

| Or. en |
and be transparent;

Amendment 968
Pietro Fiocchi

Motion for a resolution
Paragraph 63

Motion for a resolution

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

Amendment

63. Calls for assessing the possibility for the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; calls on the Commission to make an assessment of the ICU joint procurement initiative and take the lesson learned to improve this tool; considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with Directive 2014/24/EU on public procurement in a transparent manner, while respecting the following conditions: the procurement process, criteria, timelines, specifications, and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;

Amendment 969
Aldo Patriciello

Motion for a resolution
Paragraph 63

63. **Strongly advocates** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

63. **Calls for assessing the possibility for** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; **calls on the Commission to make an assessment of the ICU joint procurement initiative and take the lesson learned to improve this tool;** considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with Directive 2014/24/EU on public procurement in a transparent manner, while respecting the following conditions: the procurement process, criteria, timelines, specifications, and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;

---

Motion for a resolution

63. **Strongly advocates** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

Amendment

63. **Acknowledges the possibility for** the extension of joint procurement procedures **on the basis of a joint assessment of the value of the product,** for cancer medicines to improve affordability and access to cancer treatments at EU level; **insists that a thorough impact assessment taking stock of the current and ongoing experience of EU joint procurements would be needed prior to expand this tool to additional areas; stresses that EU joint procurement should be used only in exceptional circumstances and for extraordinary public cross-border health threats where access to medicines cannot be ensured as efficiently by other means;**

Or. en

Amendment 971
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 63

Motion for a resolution

63. **Strongly advocates the extension of** joint procurement procedures for cancer medicines **to** improve affordability and access to cancer treatments at EU level;

Amendment

63. **Points out that** joint procurement procedures for cancer medicines **could** improve affordability and access to cancer treatments at EU level;

Or. en

Amendment 972
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 63
63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; 

Amendment

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; considers, in this respect, that special attention should be given to paediatric cancers and rare cancers;

Amendment 973
Alin Mituța, Nicolae Ștefănuță, Hilde Vautmans, Vlad Gheorghe

Motion for a resolution
Paragraph 63

Motion for a resolution

63. Strongly advocates the extension of joint procurement procedures for cancer medicines and cancer preventing vaccines like HPV and hepatitis B vaccines to improve affordability and access to cancer treatments at EU level;

Amendment

63. Strongly advocates the extension of joint procurement procedures for cancer medicines and cancer preventing vaccines like HPV and hepatitis B vaccines to improve affordability and access to cancer treatments at EU level;

Amendment 974
Bronis Ropė

Motion for a resolution
Paragraph 63

Motion for a resolution

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

Amendment

63. Strongly advocates the centralisation and extension of joint European procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;
Amendment 975
Pietro Fiocchi

Motion for a resolution
Paragraph 63

Motion for a resolution

63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;

Amendment

63. Strongly advocates the extension of joint procurement procedures for cancer health technologies to improve affordability and access to cancer treatments in all Member States;

Or. en

Amendment 976
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 63 a (new)

Motion for a resolution

63a. Considers that it is crucial to reduce inequalities within EU healthcare systems, as well as discrepancies between the approval and access to medicines; recommends, therefore, that the mandatory uptake of joint clinical assessments under the HTA regulation be considered, to provide equal access to optimal cancer care to all patients;

Amendment

Or. en

Amendment 977
Joëlle Mélin

Motion for a resolution
Paragraph 64
Motion for a resolution

64. Calls for a review of data exclusivity in the authorisation process of medicines\(^{29}\), i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;


Amendment 978
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyrači, Dolores Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak

Motion for a resolution
Paragraph 64

64. Calls for a review of data exclusivity in the authorisation process of medicines\(^{29}\), i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can

64. Calls on the Commission to support a regulatory framework which strengthens incentives for rare cancer treatment in the EU to effectively address existing shortcomings; underlines that the patent systems all over the world are drafted in a way that for a specific period
allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;

of time, i.e. only for the duration of the patent, the inventor is allowed to commercially exploit its patent, whereas thereafter the invention can be freely exploited by anyone; calls on the Commission to develop new targeted incentives to ensure equitable access to cancer medicines also in areas where the development of products would otherwise not be sustainable;


Amendment 979
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 64

Motion for a resolution

64. Calls for a review of data exclusivity in the authorisation process of medicines, i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;

29 In particular Article 14 of Regulation
Amendment 980
Michèle Rivasi

Motion for a resolution
Paragraph 64

64. Calls for a review of data exclusivity in the authorisation process of medicines\textsuperscript{29}, i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;

Amendment 981
Pietro Fiocchi

Motion for a resolution
Paragraph 64

64. Calls for a review of data exclusivity in the authorisation process of medicines, i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;


Or. en

Amendment 982
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 64 a (new)

64a. Welcomes the Commission initiative to revise the EU legislation on medicines for orphan, paediatric and rare diseases that will benefit patients
suffering from cancers with low incidence and few treatment options, especially in the area of paediatric oncology;

Amendment 983
Joëlle Mélin

Motion for a resolution
Paragraph 65

65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products\(^\text{30}\) in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;

Amendment 984
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak

Motion for a resolution
Paragraph 65

65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies' compliance with the requirements on transparency;

65. Calls on the Commission and Member States to support pricing models based on real production costs, innovation and value to patients; calls also on the Commission to investigate novel pricing and payment models and their possible impact on patient access to innovative medicines, in particular cancer medicines;

Amendment 985
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 65

Motion for a resolution

65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products\textsuperscript{30} in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Amendment

65. Calls on the Commission to launch an in-depth assessment on the need to review Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products\textsuperscript{30}; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Or. en

Amendment 986
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 65
65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Amendment 987
Michèle Rivasi

Motion for a resolution
Paragraph 65

65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure, under the framework of Member States internal regulations, effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds;


Or. en
products in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; calls on the Commission to promote and facilitate information-sharing among Member States on the net prices of medicines and to contribute to the implementation of the World Health Assembly (WHA) Resolution on Improving the transparency of markets for medicines, vaccines and other health products, which calls for taking appropriate measures to publicly share information on net prices;


Amendment 988
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 65
65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Amendment

65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls on competent authorities to request pharmaceutical companies to provide information on financing with public resources, prior to marketing authorization, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Or. en
89/105/EEC on the transparency of measures regulating the prices of medicinal products\textsuperscript{30} in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


Amendment 990
Marian-Jean Marinescu

Motion for a resolution
Paragraph 65 a (new)

\emph{Motion for a resolution}

65a. Calls on the Commission to develop a fair pricing model for medicinal products, in particular for cancer medicines, that would reflect the real cost of research and production, include a justified limit for expenditures on marketing, take into consideration sustainable profitability for the industry

\emph{Amendment}

Or. ro
and introduce a bonus system that rewards the added therapeutic value;

Amendment 991
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 65 b (new)

Motion for a resolution

Amendment

65b. Calls on the Commission to promote the revision of the Paediatric regulation aimed at resolving the gap in paediatric cancer products, which represent less than 20% of adult cancer approved products;

Amendment 992
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 65 c (new)

Motion for a resolution

Amendment

65c. Calls on the EMA, Commission and Member States to assess the efficacy and outcomes of cancer treatments, allowing for more personalised treatment and outcome based reimbursement;

Amendment 993
Alessandra Moretti

Motion for a resolution
Paragraph 66
Motion for a resolution

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

highlights the fact that the research community, including scientific societies, are conducting extensive research in the area of precision medicine; calls for the inclusion of existing and ongoing research, especially in the area of oncology, to be taken into account while implementing the actions of Europe’s Beating Cancer Plan focusing on personalised medicine, including the European Cancer Imaging Initiative, the Partnership on Personalised Medicine, the Roadmap towards Personalised Prevention and the new digital platforms;

Or. en

Amendment 994
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 66
and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

and that precision or personalised medicine can be made available through the drug targeting of various tumour cell genotypes/phenotypes; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour genotypes/phenotypes, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; notes that the fragmentation and classification of cancers, based on specific genotypes, should not lead to the definition of "artificial rare diseases" to increase financial compensation;

Amendment 995
Michèle Rivasi

Motion for a resolution
Paragraph 66

Motion for a resolution

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

Amendment

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; stresses the need for a careful consideration of personalised medicines for prevalent diseases, including some cancer
indications, which should not fall within the remit of the orphan medicinal products regulation in order to prevent an unsustainable incentive system;
can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;
Amendment 999
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 66

Motion for a resolution

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

Amendment

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to develop personalised medicine across the EU through cooperation between Member States and data interoperability, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

Or. en

Amendment 1000
Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen

Motion for a resolution
Paragraph 66

Motion for a resolution

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug

Amendment

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug
targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to increase the awareness of personalised medicine among healthcare professionals and patients, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

Or. en

Amendment 1001
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 66

66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients;

Or. en

Amendment 1002
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara
Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 66 a (new)

Motion for a resolution

Amendment

66a. Highlights the fact that the research community, including scientific societies, are conducting extensive research in the area of precision medicine; calls for the inclusion of existing and ongoing research, especially in the area of oncology, to be taken into account while implementing the actions of Europe’s Beating Cancer Plan focusing on personalised medicine, including the European Cancer Imaging Initiative, the Partnership on Personalised Medicine, the Roadmap towards Personalised Prevention and the new digital platforms;

Or. en

Amendment 1003
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 67

Motion for a resolution

Amendment

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long-term learning from the COVID-19
Amendment 1004
Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen

Motion for a resolution
Paragraph 67

Motion for a resolution

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

Amendment

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long term learning from the COVID-19 pandemic on future forms of international trial cooperation and information-sharing;


Amendment 1005
Alexis Georgoulis

Motion for a resolution  
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

__________________


Amendment

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long-term learning from the COVID-19 pandemic on future forms of international trial cooperation and information-sharing;

__________________


Or. en

Amendment 1006
Alessandra Moretti

Motion for a resolution  
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and

PE697.581v01-00  94/187  AM\1239353EN.docx
improve cancer patients’ and their families’ quality of life;
improve cancer patients’ and their families’ quality of life; considers, furthermore, that the regulation should be applied in a consistent manner in all EU Member States with the aim of rationalising the bureaucratic burden associated with clinical research;


Amendment 1007
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\textsuperscript{31}; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;


Amendment

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\textsuperscript{31}; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; considers, furthermore, that the regulation should be implemented in a consistent manner in all EU Member States;


Amendment 1008
Antoni Comín i Oliveres
Motion for a resolution
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;


Amendment

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate anticipatory and responsive research into cancer drugs and improve cancer patients’ and their families’ quality of life;


Or. en

Amendment 1009
Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

-------------

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials across Europe carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

-------------
Motion for a resolution
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

---

Amendment 1010
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 67

67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use\(^{31}\); considers that the application of the regulation would facilitate the launch of large clinical trials carried out across Europe in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life;

---

Amendment 1011
Lídia Pereira

Motion for a resolution
Paragraph 67 a (new)

67a. Recognises the prodigious impact that the Regulation on orphan medicinal products (EC/141/2000)\(^{1a}\) has had on developing innovative medicines, including for rare cancers; acknowledges that many cancers are rare diseases; invites, therefore, the Commission to
maintain the philosophy of this Regulation, namely incentives and current disease thresholds to allow for continuous investment in rare cancers.


Amendment 1012
Alin Mituța, Nicolae Ștefănuță, Hilde Vautmans, Vlad Gheorghe

Motion for a resolution
Paragraph 67 a (new)

Motion for a resolution
Amendment

67a. Points out that the PRIME scheme launched by the European Medicines Agency can be a great instrument to enhance support for the development of innovative medicines in oncology so that they can reach the patient sooner;

Amendment 1013
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 68

Motion for a resolution
Amendment

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for
cancers with a poor prognosis and rare cancers; rapidly test existing molecules and new drug combinations, starting with **high unmet needs**, treatment for cancers with a poor prognosis and rare cancers; **suggests an EU cancer policy goal to double the survival rate for cancers with poor prognosis to connect across EU related initiatives;**

**Amendment 1014**
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

**Motion for a resolution**
**Paragraph 68**

*Motion for a resolution* 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

*Amendment* 68. Calls for a more sustainable environment **including financial support** for conducting research into the repurposing of medicines for cancer treatment, **especially performed by third parties with no commercial intent** and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with **high unmet needs**, treatment for cancers with a poor prognosis and rare cancers;

**Amendment 1015**
Michèle Rivasi

**Motion for a resolution**
**Paragraph 68**
Motion for a resolution

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Amendment

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; calls for a legal framework for the clinical development of repurposed medicines for indications with high unmet needs performed by non-commercial entities, including for the EMA to be given the authority to require labelling changes following assessment of the clinical data from the non-profit research;

Or. en

Amendment 1016
Alexis Georgoulis

Motion for a resolution
Paragraph 68

Motion for a resolution

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Amendment

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; suggests an EU cancer policy goal of doubling survival for poor prognosis tumours to connect across EU related initiatives;

Or. en
Amendment 1017
Pietro Fiocchi

Motion for a resolution
Paragraph 68

Motion for a resolution

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Amendment

68. Calls for a more sustainable and extensible environment for conducting new studies and analysing existing research on the repurposing of medicines for cancer treatment, reappraising the functionality of established therapies, and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Or. en

Amendment 1018
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 68

Motion for a resolution

68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Amendment

68. Calls for a more sustainable and responsive environment for conducting anticipatory and responsive research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers;

Or. en
Amendment 1019
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 68 a (new)

Motion for a resolution 68a. Stresses the need to promote the innovation of life-saving cancer treatments; calls, therefore, on the Commission to create a pharmaceutical legislation framework and reimbursement system for oncological medicines and therapies, which incentivizes real breakthrough innovations, rather than the so-called ‘me too’ pharmaceuticals, which are just another substance for the same indication without major benefits, or the highly expensive pharmaceuticals that offer only minor improvements for patients; considers that resources should instead be concentrated on innovative, life-changing technologies, such as immunotherapy, genomic research (mRNA and CRISPR), DNA sequencing, cell therapy, precision and personalized medicines and microbiome treatments;

Amendment

Or. en

Amendment 1020
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 68 b (new)

Motion for a resolution 68b. Acknowledges that many
upcoming technologies will require complex regulations (cell and gene therapies, for example); considers that Europe should fund, incentivize and ensure a regulatory process that actively helps and encourages research and innovation, anticipating the needs of researchers in academia, industry and the clinic, actively informing and guiding them on regulatory processes, preparing the ground for future technologies and evaluating them step by step, fostering the entry of safe and effective new treatments to the market;

Or. en

Amendment 1021
Bronis Ropė

Motion for a resolution
Paragraph 68 c (new)

Motion for a resolution Amendment

68c. Welcomes the increasing availability of personalised cancer therapies through the development of drug repurposing strategies; calls for the wider use of previously developed personalised medicine drugs through a strategy of molecular targets rather than disease localisation in the selection of treatments, through the development of DRUP-type (drug rediscovery protocol) projects;

Or. lt

Amendment 1022
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 69
Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Reiterates the importance of generating and reporting strong evidence on the efficacy and safety profiles of medicines, both in clinical trials and in post-market entry follow-up studies; supports the development of clinical trials on the use of new cancer drugs in adults and children; underlines that authorities must ensure transparency, compliance with study conduct requirements and early communication of relevant data to the EMA and the general public;

Or. en

Amendment 1023
Tudor Ciuhodaru

Motion for a resolution
Paragraph 69

Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and promotes greater investment of EU and national research and innovation funds in surgical oncology research;

Or. en

Amendment 1024
Joëlle Mélin

Motion for a resolution
Paragraph 69
Motion for a resolution

Amendment

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children, as called for, for example, in the European Parliament resolution of 15 December 2016 on the regulation on paediatric medicines P8_TA(2016)0511;

Amendment 1025
Alessandra Moretti

Motion for a resolution
Paragraph 69

Motion for a resolution

Amendment

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; 69. Supports the development of clinical trials for the development of more effective and safer forms of treatment, therapies and care for cancer patients, including children and the elderly;

Amendment 1026
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 69

Motion for a resolution

Amendment

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; 69. Supports the development of clinical trials across the EU, for the invention of improved forms of treatment and care for patients, including children and older patients;
Amendment 1027
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 69

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials for the discovery of improved forms of treatment and care for patients, including children and older patients;

Or. en

Amendment 1028
Hilde Vautmans, Irena Joveva, Alin Mituța

Motion for a resolution
Paragraph 69

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials for the discovery of improved forms of treatment and care for patients, including children and older patients;

Or. en

Amendment 1029
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 69

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials and research across Europe on the use of new cancer drugs in adults and children;
Amendment 1030
Ivars Ijabs, Alin Mituța, Irena Joveva, Hilde Vautmans, Nicolae Ștefănuță

Motion for a resolution
Paragraph 69

Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials on the use of new and affordable cancer drugs in adults and children;

Amendment 1031
Loucas Fourlas

Motion for a resolution
Paragraph 69

Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials on the use across Europe of new cancer drugs in adults and children;

Amendment 1032
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 69
Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials across Europe on the use of new cancer drugs in adults and children;

Or. en

Amendment 1033
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 69

Motion for a resolution

69. Supports the development of clinical trials on the use of new cancer drugs in adults and children;

Amendment

69. Supports the development of clinical trials across Europe on the use of new cancer drugs in adults and children;

Or. en

Amendment 1034
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 69 a (new)

Motion for a resolution

69a. Supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and considers it necessary to promote greater investment of EU and national research and innovation funds in surgical oncology research;

Amendment

Or. en
Amendment 1035
Peter Liese, Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyra, Dolores Montserrrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 69 a (new)

Motion for a resolution  Amendment

69a. Supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and promotes greater investment of EU and national research and innovation funds in surgical oncology research;

Or. en

Amendment 1036
Giorgos Georgiou, Kateřina Konečná, João Pimenta Lopes, Alexis Georgoulis

Motion for a resolution
Paragraph 70

Motion for a resolution  Amendment

70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;

deleted

Or. en
Amendment 1037
Joëlle Mélin, Angelo Ciocca

Motion for a resolution
Paragraph 70

Motion for a resolution

70.  *Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;*

Amendment

70.  *Strongly supports cooperation among Member States in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;*

Or. fr

Amendment 1038
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 70

Motion for a resolution

70.  *Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and*

Amendment

70.  *Takes note of the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and*
NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; stakeholders, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;

Amendment 1039
Adam Jarubas

Motion for a resolution
Paragraph 70

Motion for a resolution

70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;
costs of the most innovative and effective therapies will increase their wider availability for the benefit of patients in the EU and beyond; calls for securing equal access to innovative therapies, both in the densely populated urban regions and smaller, rural or remote areas;

Or. en

Amendment 1040
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 70

70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; considers that HERA should closely collaborate with public and private entities to plan, coordinate and build an ecosystem of private and public capabilities which can provide suitable emergency frameworks for EU access to key raw materials in case of global supply
70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;
70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; urges that health workforce planning and resilience be within the remit of the Health Emergency Preparedness and Response Authority;

Amendment

70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; urges that health workforce planning and resilience be within the remit of the Health Emergency Preparedness and Response Authority;
options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;

Amendment 1044
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 70 a (new)

Motion for a resolution

70a. Notes that there is growing evidence that adequate supportive care measures lead to better outcomes and improve the quality of life of cancer patients; points out, in particular, that failure to monitor and assess the nutritional status of cancer patients leads to weight and muscle loss, may undermine the effectiveness of treatments and significantly increase the risk of serious side effects, as well as mortality rates; calls on Member States to make nutritional care a mandatory and fully integrated component of high-quality care throughout the implementation of Europe’s Beating Cancer Action Plan, as taking action to ensure early access of patients to proactive nutritional care has the potential to prevent treatment-limiting side effects, allowing more patients to benefit from advances in cancer treatments, whilst improving the quality of life and survival time;

Amendment 1045
Hilde Vautmans, Irena Joveva
Motion for a resolution
Paragraph 70 b (new)

Motion for a resolution

Amendment

70b. Calls on Commission and Member States to look for private-public partnerships in setting quality standards, developing production capabilities and a hospitable regulatory environment concerning innovative therapies such as Cellular Therapy, immunotherapy and robotic surgery;

Or. en

Amendment 1046
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 70 c (new)

Motion for a resolution

Amendment

70c. Highlights the importance of addressing the issue of off-label use of medicines, including inexpensive medicines, medicines used for rare cancers among others; calls on the Commission to analyse the existing situation concerning off-label use of medicines;

Or. en

Amendment 1047
Alessandra Moretti

Motion for a resolution
Paragraph 70 c (new)
70c. Highlights the importance of addressing the issue of off-label use of medicines, including inexpensive medicines, medicines used for rare cancers among others; calls on the Commission to analyse the existing situation concerning off-label use of medicines;

Amendment 1048
Margaret de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Subheading III.c

Motion for a resolution

III.c . Equal access to cancer care: towards a better response to the impact of health crises on cancer patients

Amendment

III.c . Equal access to comprehensive, multidisciplinary and quality cancer care: towards a better response to the impact of health crises on cancer patients

Amendment 1049
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estarás Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Subheading III.c

III.c . Equal access to cancer care: towards a better response to the impact of health crises on cancer patients

Amendment

III.c . Equal access to integrated, multidisciplinary and quality cancer care: towards a better response to the impact of health crises on cancer patients
Amendment 1050
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 71

Motion for a resolution

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

Amendment

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays and postponements of prevention schemes, clinical trials, screenings, referral and surgical procedures, treatment, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and poor communication among health professionals of different categories;

Amendment 1051
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 71

Motion for a resolution

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

Amendment

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in prevention activities such as HPV vaccination, screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; highlights evidence
suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;

Or. en

Amendment 1052
Pietro Fiocchi

Motion for a resolution
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; 

Amendment

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in prevention activities such as HPV vaccination, screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;

Or. en
Motion for a resolution
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;

Amendment

71. Underlines that the COVID-19 crisis has led to an increase in undiagnosed cancers and had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in prevention activities such as HPV vaccination, screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;
referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

Amendment 1055
Alessandra Moretti

Motion for a resolution
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

Amendment

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening and prevention activities like HPV vaccination, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages, reduced communication with health professionals;

Amendment 1056
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of

Motion for a resolution

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of
the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; 

the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; 

highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;

Amendment 1057
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 71

Motion for a resolution

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;

Amendment

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages, reduced communication with health professionals, patients’ fear of infection and impairments in diagnostics and treatment of diseases considered as risk factors for cancer, such as viral infections;
Amendment 1058  
Margarita de la Pisa Carrión  
Motion for a resolution  
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;  

Amendment  

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals and patients’ fear of infection;  

Or. en

Amendment 1059  
Ondřej Knotek, Irena Joveva  
Motion for a resolution  
Paragraph 71

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;  

Amendment  

71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral, diagnosis and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals;  

Or. en
Amendment 1060
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 71 a (new)

Motion for a resolution

Amendment

71a. Deplores the fact that patients still face many difficulties in accessing quality, public health care services since many oncology departments at public hospitals are suffering from workforce shortages and lack of capacity; calls, therefore, for the creation of high-quality radiotherapy departments and modern oncology centres at public hospitals, based on European guidelines and in line with the most recent scientific evidence;

Or. en

Amendment 1061
Søren Gade

Motion for a resolution
Paragraph 72

Motion for a resolution

Amendment

72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients;

72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that vulnerable groups, including cancer patients, are particularly exposed during a health crisis; stresses that specific measures under this emergency strategy – including e.g. advance purchase agreements (APAs) – should support the development, production and stockpiling of products to protect these vulnerable groups;
Amendment 1062  
Bartosz Arłukowicz  
Motion for a resolution  
Paragraph 72  

72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients;

Amendment 1063  
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes  
Motion for a resolution  
Paragraph 72  

72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react **accordingly in times of** any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; **calls for the creation of structures that can strengthen cooperation on health policy at EU level, including through the creation of a committee or sub-committee on health in the European Parliament**;
Amendment 1064
Nicolás González Casares, María Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 72

72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; and the protection of health as a human right and a public good;

Amendment
72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups that cannot wait until the end of the crisis, including cancer patients;

Amendment 1065
Nicolás González Casares, Alessandra Moretti, María Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 72 a (new)

72a. Calls on the Commission and the Member States to diligently collect data via suitable registries to monitor the
effects of vaccines in the vulnerable population, including patients with cancer and their immune response;

Amendment 1066
Alessandra Moretti

Motion for a resolution
Paragraph 72 a (new)

Motion for a resolution

72a. Calls on the Commission and the Member States to diligently collect data via suitable registries to monitor the effects of vaccines in the vulnerable population, including patients with cancer and their immune response;

Amendment 1067
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 73

Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; recognises that the pandemic has exacerbated the crucial role of informal carers, who provide most of the daily care for cancer patients and who face a clear
lack of support (may it be in terms of social rights, training, psychological help, information, recognition); calls on the Commission and the Member States to create online training platforms as well as therapeutic care programmes granting qualifications and recognising their competences;

Amendment 1068
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 73

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment
73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;
recognises the fact that the pandemic has increased the care burden for informal carers, who provide most of the daily care required by cancer patients and who need (practical and policy) support;

Amendment 1069
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 73
Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing workforce shortages of the public health sector; acknowledges the urgency of ensuring a sufficient number of specialised health professionals especially in public healthcare systems; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; underlines that new approaches for human-centred healthcare are required in order to ensure access to diagnostics, therapeutics and quality public health services for all;

Or. en

Amendment 1070
Bartosz Arłukowicz

Motion for a resolution
Paragraph 73

Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; stresses the need for work on a skill mix in order to optimise the response to staffing needs in the health sector; supports the exchange of good practices between Member States in this regard;

Or. pl
Amendment 1071
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Špyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 73

Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; underlines the need to work on the so-called skill-mix in order to optimise the response on the workforce shortages in healthcare; supports the exchange of best practices between Member States in that area;

Or. en

Amendment 1072
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 73

Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that
specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;
suggests that the Cancer Inequalities Registry may serve a function in measuring and reporting on pre-existing workforce shortages;

Amendment 1073
Alexis Georgoulis

Motion for a resolution
Paragraph 73

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; suggests that the Cancer Inequalities Registry may serve as a tool in measuring and reporting on workforce shortages;

Amendment 1074
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 73

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; suggests that the Cancer Inequalities Registry may serve as a tool in measuring and reporting on workforce shortages;
existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care, doctors and nurses; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals in both primary and specialized care;

Amendment 1075
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 73

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;
73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals in both primary and specialised care;

Or. en

Amendment 1077
Tudor Ciuhodaru

Motion for a resolution
Paragraph 73

Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals and their retraining should they be specialists in other fields;

Or. ro

Amendment 1078
Joëlle Mélin

Motion for a resolution
Paragraph 73
Motion for a resolution

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

therefore encourages the Member States to drop numerus clausus policies;

Amendment

73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals;

Or. fr

Amendment 1079
Bartosz Arłukowicz

Motion for a resolution
Paragraph 73 a (new)

Motion for a resolution

73a. Stresses the urgent need for the European Union to support measures to maintain the continuity of use of health systems during and after the pandemic in order to eliminate delays in diagnosis and treatment for cancer patients;

Or. pl

Amendment 1080
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 74

Motion for a resolution

74. Advocates the development of a digital health system to monitor symptoms

Amendment

74. Advocates the development of a digital health system to monitor symptoms
and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

and ensure cancer treatment and care at home; encourages the creation of a secure digital communication channel enabling health professionals to monitor patients' symptoms remotely; calls for permanent access to medical and nutrition consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; calls for cross-sector and cross-country collaboration and knowledge sharing that will be crucial for further enhancing the quality of cancer care in the EU;

Or. en

Amendment 1081
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home but without forgetting the value of face-to-face care and training provided by professional carers; calls for permanent access to medical consultations, nursing and psychosocial services to be guaranteed through the use of telemedicine and telecare or in health threat-free environments in hospitals;

Or. en

Amendment 1082
Pietro Fiocchi

Motion for a resolution
Paragraph 74
Motion for a resolution

Paragraph 74

Amendment

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; **calls for the stimulation of the development of therapeutics that can support a transition to home care;**

Or. en

Amendment 1083
Bartosz Arłukowicz

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; **as well as contact between patient and doctor and between the attending doctor and the patient's family, to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;**

Or. pl

Amendment 1084
Joëlle Mélin

Motion for a resolution
Paragraph 74
74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home, in strict accordance with patient confidentiality and the GDPR; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

Or. fr

Amendment 1085
Pietro Fiocchi

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure continued cancer treatment in out-of-hospital care; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine technologies or safe hospitals in the event of a public health crisis or major event;

Or. en

Amendment 1086
Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure continued cancer treatment in out-of-hospital care; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine technologies or safe hospitals in the event of a public health crisis or major event;
and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

and ensure cancer treatment and care outside hospital; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

Amendment 1087
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use and integration of telemedicine within the healthcare systems or in health threat-free environments in hospitals;

Amendment 1088
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 74

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;

74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals;
environments in hospitals; environments in hospitals or, when possible and safe, pharmacies;

Or. en

Amendment 1089
Adam Jarubas, Ewa Kopacz

Motion for a resolution
Paragraph 75

Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises, as well as information on how to eliminate or limit harm caused by certain behaviours, including choosing less harmful alternative products if other options fail;

Or. en

Amendment 1090
Michèle Rivasi

Motion for a resolution
Paragraph 75

Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises, which can be performed by national civil societies organisations, if
75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;
Amendment 1093
Nicolae Ștefânuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 75

Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, patients, parents, survivors and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Or. en

Amendment 1094
Loucas Fourlas

Motion for a resolution
Paragraph 75

Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, parents, patients, survivors and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Or. en

Amendment 1095
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 75
Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, patients, survivors and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns for prevention and risk reduction in times of crises;

Or. en

Amendment 1096
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 75

Motion for a resolution

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises;

Amendment

75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns for prevention and risk reduction in times of crises;

Or. en

Amendment 1097
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 76

Motion for a resolution

76. Calls on the Commission and the Member States to adopt European

Amendment

76. Calls on the Commission and the Member States to adopt European
prevention and management plans to address cancer drug shortages in times of health crises;
Amendment 1099
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 76

Motion for a resolution
76. Calls on the Commission and the Member States to adopt European prevention and management plans to address cancer drug shortages in times of health crises;

Amendment
76. Calls on the Commission and the Member States to adopt European prevention and management plans as part of a coherent and holistic contingency strategy to prevent and address shortages of medicines, devices, products and staff in times of health crises;

Or. en

Amendment 1100
Alexis Georgoulis

Motion for a resolution
Paragraph 76

Motion for a resolution
76. Calls on the Commission and the Member States to adopt European prevention and management plans to address cancer drug shortages in times of health crises;

Amendment
76. Calls on the Commission and the Member States to adopt European prevention and management plans as part of a coherent and holistic contingency strategy to prevent and address shortages of medicines, devices, products and staff in times of health crises;

Or. en

Amendment 1101
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 76

Motion for a resolution
76. Calls on the Commission and the

Amendment
76. Calls on the Commission and the

PE697.581v01-00 144/187
Member States to adopt European prevention and management plans to address cancer drug shortages in times of health crises;

Member States to adopt European prevention and management guidelines and enforce transparency over the supply and provision of cancer drug shortages in times of health crises;

Or. en

Amendment 1102
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 76 a (new)

Motion for a resolution

Amendment

76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;

Or. en

Amendment 1103
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 76 a (new)

Motion for a resolution

Amendment

76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;

Or. en
Amendment 1104
Alexis Georgoulis

Motion for a resolution
Paragraph 76 a (new)

Amendment
76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;

Or. en

Amendment 1105
Margarita de la Pisa Carrión

Motion for a resolution
Subheading IV

Amendment
IV. Strong support to cancer patients, survivors and caregivers

Or. en

Amendment 1106
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 77

Amendment
77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of an anti-discrimination directive, as well as for the fair and equal implementation of directives on financial services, such as the

77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive

Or. en
Consumer Credit Directive\textsuperscript{32}, without any discrimination against cancer patients and survivors;


Amendment 1107
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 77

\textit{Motion for a resolution}

77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of an anti-discrimination \textit{directive}, as well as for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive\textsuperscript{32}, without any discrimination against cancer patients and survivors;


\textit{Amendment}

77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of a set of recommendations on anti-discrimination, as well as for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive\textsuperscript{32}, without any discrimination against cancer patients and survivors;


Or. en

Amendment 1108
Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 77 a (new)
Motion for a resolution

Amendment

77a. Calls on the Commission and Member States to design information and awareness raising campaigns in order to eliminate cancer-related stigma

functioning at the same time as a tool to improve screening, early diagnosis and survival rates;

1a https://www.livestrong.org/sites/default/files/what-we-do/reports/lsglobalresearchreport.pdf


Or. en

Amendment 1109
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 77 b (new)

Motion for a resolution

Amendment

77b. Calls on the Commission to consider an EU Strategy on Care and Caring, to ensure appropriate, accessible, and high-quality long-term care;

Or. en

Amendment 1110
Alexis Georgoulis

Motion for a resolution
Paragraph 77 c (new)
Motion for a resolution

77c. Calls on the Commission and the Member States to include in their taxation policies measures such as tax reductions or exemptions in order to support and relieve cancer patients and their caregivers;

Amendment

Or. en

Amendment 1111
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 77 d (new)

Motion for a resolution

77d. Calls on the Commission and the Member States to design policies supporting the re-introduction of cancer patients to the labour market, including measures such as tools to motivate employers, as well as tools to educate and train patients in case they need to change their career path;

Or. en

Amendment 1112
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78

Motion for a resolution

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance,

Amendment

78. Emphasises the importance of specific EU recommendations to improve the essential issues in the treatment of all cancer patients and their families, including via supportive integral care, from a bio-psycho-social perspective (pain
access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

relief, psychological services, adapted physical activity, nutritional support, social assistance and restoration of aesthetic integrity) integrated into cancer care from diagnosis and throughout the entire disease; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Or. en

Amendment 1113
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment
78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via comprehensive supportive care from a bio-psycho-social perspective (pain relief, psychological services, adapted physical activity, scientific evidence-based complementary therapies, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity) and integrated into cancer care from diagnosis and throughout the disease process; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; recognizes the importance of palliative care as special care for people with life threatening illness and their families, relieving pain and physical, psychosocial and spiritual suffering, while benefitting health systems; highlights that NCCPs should offer palliative care and a Pain
Management Plan for everyone who needs it, for the entire disease trajectory from the beginning and alongside the disease, for adults and also for children; urges the EU to work with Member States to address barriers for palliative care, to provide palliative care through primary health care centres as well as at home, and promote palliative care education for all health professionals;

Or. en

Amendment 1114
Nathalie Colin-Oesterlé

Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Recognises that cancer is a financially burdensome disease, even beyond cancer treatments; emphasises the importance of specific EU recommendations to improve the quality of life of patients, including supportive care (pain relief, psychological services, adapted physical activity, complementary therapies, nutritional support, social assistance encompassing all day-to-day tasks such as household help or child care, access to reproductive health and restoration of aesthetic integrity); recognizes that these types of supportive care are often only developed by private health insurances; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; asks the Commission to propose guidelines for Member States to address the importance of establishing comprehensive coverage systems that guarantee these needs;

Or. en
Amendment 1115
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Špyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity), and access to specialised supportive centres; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; calls on the Commission to set up a platform for the exchange of best practice in palliative care and support research in palliative care; calls on Member States to include the aspect of pain management for patients in treatment and survivors;

Or. en

Amendment 1116
Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological
services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; 

notes that there is a need to focus on the quality of life for a rising number of chronic cancer patients whose illness cannot be cured but which may be stabilised for a number of years; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment 1117
Pietro Fiocchi

Motion for a resolution
Paragraph 78

Motion for a resolution

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States to do more in recognising sequelae (physical or mental disabilities), as well as confronting social stigma and discrimination, which can limit opportunities for employment and social interaction;

Amendment 1118
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis
Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients and survivors, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity) from the diagnosis and during the whole treatment; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Or. en

Amendment 1119
Joëlle Mélin

Motion for a resolution
Paragraph 78

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients and survivors, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, support for managing comorbidities, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social hardship;

Or. fr
Amendment 1120
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 78

Motion for a resolution

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination, including in the workplaces;

Or. en

Amendment 1121
Michèle Rivasi

Motion for a resolution
Paragraph 78

Motion for a resolution

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Or. en
Amendment 1122
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 78

Motion for a resolution

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Amendment

78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, access to education, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination;

Or. en

Amendment 1123
Pietro Fiocchi

Motion for a resolution
Paragraph 78 a (new)

Motion for a resolution

78a. Draws attention to the estimation that between 10% and 20% of the 1.3 million cancer deaths in the EU in 2020 can be attributed to malnutrition, rather than cancer itself (ESPEN practical guideline: Clinical Nutrition in cancer); calls for incorporating clinical nutrition in all aspects of cancer treatment, including cancer screening, cancer treatment, cancer support and cancer research; recognizes that all cancer patients should be screened for malnutrition and, wherever indicated, they must be provided with clinical nutritional support in addition to other therapies by qualified personnel; recommends that nutrition management
be an integral ethical part of all research involving cancer patients, including clinical research; also recommends that proper nutritional support be included in the cancer patients' Charter of Rights;

Amendment 1124
Bronis Ropè

Motion for a resolution
Paragraph 78 b (new)

Motion for a resolution

78b. **Strongly urges the Member States to ensure that all cancer patients are fully informed about the possibility of fertility preservation procedures prior to the start of active treatment; calls for the development of guidelines at EU level for health professionals, defining the age at which cancer patients should be informed about the availability of reproductive health procedures; encourages, furthermore, the Member States to make provision for all cancer patients covered by compulsory national health insurance to be reimbursed for such services by national health insurance schemes;**

Amendment 1125
Michèle Rivasi

Motion for a resolution
Paragraph 78 c (new)

Motion for a resolution

78c. **Underlines that surveys demonstrate that around 37% of cancer patients use complementary treatments in**
addition to their conventional cancer treatment; calls for inclusion of holistic treatment methods in cancer centres using the combination of conventional and complementary therapies, also known as integrative oncology, including fostering the development of a high quality multidisciplinary workforce to improve patients’ quality of life and well-being, including mental, psychosocial and nutritional support; calls for increased research investment to assess the validity of the integrative approach of cancer care;

Amendment 1126
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 78 d (new)

Motion for a resolution
Amendment

78d. Notes that up to 10-20% of cancer patients die due to consequences of malnutrition rather than for the tumour itself; calls for clinical nutrition to be incorporated in all aspects of cancer treatment; recognizes that all cancer patients should be screened for malnutrition and, whenever indicated, cancer patients should receive clinical nutritional support by qualified personnel; recommends that proper nutritional support be included in the cancer patients’ Charter of Rights;

1a
https://www.clinicalnutritionjournal.com/action/showPdf?pii=S0261-5614%2821%2900079-0

Or. en
Amendment 1127
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78 e (new)

Motion for a resolution
Amendment

78e. Underlines that the results of cancer treatment can be hampered by malnutrition thus optimal nutritional care is essential for cancer care; calls on the Commission and Member States to ensure nutritional support to cancer patients at all stages of the disease and to take all the necessary steps to include an oncology dietitian specialist into the multidisciplinary team (MDT);

Or. en

Amendment 1128
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 78 f (new)

Motion for a resolution
Amendment

78f. Urges the Commission, Member States, regions and all public administrations to widen and seek innovative approaches for cancer treatment and management by integrating the One Health and Health in All Policies principles as cross-sectoral principles; proposes the creation of an interoperable database as a network of hospitals and specialised oncological centres, as well as fostering the development of high-quality multidisciplinary approaches in the fight against cancer;

Or. en
Amendment 1129
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lidia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 78 g (new)

Motion for a resolution Amendment

78g. Highlights the importance of encouraging the use of complementary therapies based on scientific evidences, in support of conventional treatments, in the framework of an integrative oncology, given the value of this approach in improving the quality of life of patients;

Or. en

Amendment 1130
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 78 h (new)

Motion for a resolution Amendment

78h. Encourages Member States to pay attention to the specific needs – in terms of pain relief or access to palliative care – of patients suffering from an advanced or metastatic cancer;

Or. fr

Amendment 1131
Christian Sagartz

Motion for a resolution
Paragraph 78 i (new)
Motion for a resolution

Amendment

78i. Stresses the need for medical and psychological aftercare for cancer survivors; notes the general underestimation of aftercare compared to the equally important cancer prevention;

Or. en

Amendment 1132
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78 j (new)

Motion for a resolution

Amendment

78j. Encourages Member States to facilitate the removal of excessive red tape in the assessment process of a disability related to cancer or to a cancer treatment;

Or. en

Amendment 1133
Michèle Rivasi

Motion for a resolution
Paragraph 78 k (new)

Motion for a resolution

Amendment

78k. Calls for Quality of Life (QoL) to be fully integrated in the development of cancer treatments and for the Patient Reported Outcome Measures (PROMS) to be mandatory for the registration trials leading to market authorisation; calls for enhanced use of therapy optimisation clinical trials, including de-escalation trials, with QoL as primary endpoints;

Or. en
Amendment 1134
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78 l (new)

Motion for a resolution
Amendment

78l. Calls on Member States to develop recommendations to add nutrition as a fundamental, integral and key part of an adequate treatment and care of cancer patients;

Or. en

Amendment 1135
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78 m (new)

Motion for a resolution
Amendment

78m. Acknowledges that for cancer patients, cancer survivors and for those for whom cure is no longer possible, poor nutritional status impairs quality of life and reduces survival time; calls on the Commission and Member States to protect a patient’s nutritional status across the continuum of cancer care and to provide access to appropriate nutrition support and dietetic services that meet the patient’s individual needs;

Or. en

Amendment 1136
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 78 n (new)
Motion for a resolution
78n. Welcomes the planned inter-speciality training on nutrition support; calls on the Commission and Member States to develop minimum standards for continuous training on nutritional care for the multidisciplinary workforce, including nurses, oncologists, radiotherapists, general practitioners, pre- and postgraduates and resident doctors;

Amendment

Amendment 1137
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 78 o (new)

Motion for a resolution

78o. Stresses the importance for the patient’s recovery of the company and presence of his family and loved ones as a fundamental support to find hope and peace during the difficult moments of the disease; urges that it should be a priority to ensure the necessary conditions so that these contacts can take place;

Amendment

Amendment 1138
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 78 p (new)

Motion for a resolution

78p. Calls on the Commission to encourage Member States to offer specific training in primary care for survivors and
provide medical personnel with expertise in survivorship, as well as ensure that oncologists can liaise with the primary care physician on behalf of the survivors;

---

Amendment 1139
Bartosz Arłukowicz

Motion for a resolution
Paragraph 79

Motion for a resolution

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and **rest periods in the workplace**;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and **increased flexibility in their working time, or to adapt their working time to the care needs of the patient**;

---

Amendment 1140
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 79

Motion for a resolution

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and **stronger employee protection, considering, among other options, rest periods in the workplace, increases in the number of days with justified and paid absences to support family members, leave and care allowances for direct relatives with 100%**
Motion for a resolution
Paragraph 79

Motion for a resolution

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace, as well as support during mourning; encourages also the development of integrated support schemes for cancer patients and their families, taking into account health, community and social services;

Or. en

Amendment 1142
Joëlle Mélin, Angelo Ciocca, Stefania Zambelli

Motion for a resolution
Paragraph 79

Motion for a resolution

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; calls for more carers to be trained and for day centre services to be made available for family carers;

Or. fr
Amendment 1143
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 79

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological and socio-economic assistance, especially for the most vulnerable ones, and rest periods in the workplace, along all the illness, as well as bereavement support;

Or. en

Amendment 1144
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 79

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace;

Amendment

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance rest periods in the workplace and to put in place adequate and accessible support systems;

Or. en

Amendment 1145
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel,
Motion for a resolution
Paragraph 79

79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; as well as support after death;

Amendment

79a. Calls on Member States and relevant authorities to recognise the pivotal role of informal carers, to integrate them within the health and care team and empower them with the possibility of making informed choice regarding available supportive measures;

Amendment

79a. Stresses the importance of financial and care support for families of patients who may be attending to their
needs daily, even if they have to stop their professional life;

Amendment 1148
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 79 b (new)

79b. Calls on Member States to respect a patient's decision when he/she wishes to accept suffering and its consequences in the course of the disease;

Amendment 1149
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 79 c (new)

79c. Calls on Member States to ensure that all social agents and health professionals respect the defence of life itself in the face of illness in all of their practices;

Amendment 1150
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 80
80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

Amendment

80. Recalls that patient proactivity is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education and self-care training of caregivers and patients and their engagement in the care programmes for the promotion of active and expert patients, using tools such as peer-to-peer learning;

Or. en

Amendment 1151
Bartosz Arłukowicz

Motion for a resolution
Paragraph 80

Motion for a resolution

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

Amendment

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; encourages the development of the role of treatment coordinator in each Member State, which could serve as a contact point to help patients make optimal use of the services provided by the health system;

Or. pl

Amendment 1152
Michèle Rivasi
Motion for a resolution
Paragraph 80

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

Amendment

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; calls for participatory decision-making with personalised and understandable evidence-based information provided to patients as an integral part of the National Cancer Control Programs (NCCPs), supported by the EBCP;

Or. en

Amendment 1153
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 80

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

Amendment

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; considers that given the specific characteristics and needs of paediatric patients, a specifically tailored methodology should be used for the training and empowerment process of
Motion for a resolution
Paragraph 80

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

Amendment

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; **considers that, given the paediatric specific developmental characteristics, a specifically tailored methodology should be applied to the training and empowerment process of paediatric patients;**
programmes; recommends the support of such initiatives and actions to empower cancer patients through EU funding such as the EU4Health programme;

Amendment 1156
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 80

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes;

80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; recommends that EU4Health programme supports initiatives and actions to empower cancer patients.

Amendment 1157
Peter Liese
on behalf of the EPP Group

Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolores Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 80 a (new)

80a. Points to the high percentage of informal carers among the European population and to the disparities
regarding the way they are supported and how their rights are recognized between Member States; calls on the Commission to consider the formalization of an informal caregiver status, ensuring the recognition of a certain minimum standard of rights, especially for those who are providing long-term care;

Or. en

Amendment 1158
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 80 a (new)

Motion for a resolution

Amendment
80a. Points out that more than 75% of patients diagnosed with cancer are over 60 years old and that a fully fledged geriatric approach is therefore required;

Or. fr

Amendment 1159
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 80 b (new)

Motion for a resolution

Amendment
80b. Strongly calls, therefore, for caregivers of the elderly to be made aware of the need for a fresh approach to look out for the misleading symptomatology senior citizens experience;

Or. fr
Amendment 1160
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 80 c (new)

Motion for a resolution

Amendment

80c. Urges states to work together to create a safe environment for elderly cancer patients, particularly those who are isolated;

Or. fr

Amendment 1161
Joëlle Mélin, Stefania Zambelli

Motion for a resolution
Paragraph 80 d (new)

Motion for a resolution

Amendment

80d. Therefore encourages the Member States to develop home-based care and hospitalisation systems;

Or. fr

Amendment 1162
Joëlle Mélin

Motion for a resolution
Paragraph 80 e (new)

Motion for a resolution

Amendment

80e. Encourages research into non-profit clinical trials with a view to improving treatment strategies, particularly for the elderly;

Or. fr
Amendment 1163
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 81

81. Acknowledges the **positive** role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Amendment

81. Acknowledges the **central** role of patients’ and carers’ associations in relation to patient advocacy and accompaniment, **dissemination of health literacy, and awareness and ongoing support both at EU and national level**; calls on the Commission and the Member States to **include them in upcoming financial programs and specific projects and to guarantee operational funding**, take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in **form of both operating grants and project related grants in order to guarantee their independence from private funding**;

Or. en

Amendment 1164
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 81

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Motion for a resolution

81. Acknowledges the positive role of patients’ associations **and Young Patients Advisory Groups (YPAGS)** in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; **considers that paediatric**
patients should play a role, both individually and collectively, in improving healthcare and research procedures for all patients by contributing with their specific experiences; takes the view, therefore, that adequate learning and educational tools should be developed to plan and ensure the involvement of children, which is properly financed;

Amendment 1165
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 81

Motion for a resolution

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Amendment

81. Acknowledges the positive role of patients’ associations and Young Patients Advisory Groups (YPAGS) in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; recalls the need for paediatric patients (individually and collectively) to play a role in improving healthcare and research procedures by contributing with their specific experiences; considers that adequate learning and educational tools should be developed to plan and carry out an appropriately resourced involvement of children;

Or. en
Amendment 1166
Michèle Rivasi

Motion for a resolution
Paragraph 81

Motion for a resolution

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Amendment

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; calls for the Commission to set clear criteria according to which public financial support can be awarded;

Or. en

Amendment 1167
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 81

Motion for a resolution

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Amendment

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy, accompaniment and services provided to cancer patients and caregivers; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Or. en
Amendment 1168  
Margarita de la Pisa Carrión

Motion for a resolution  
Paragraph 81

**Motion for a resolution**

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

**Amendment**

81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their formal participation, as well as their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;

Or. en

Amendment 1169  
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution  
Paragraph 81 a (new)

**Motion for a resolution**

81a. Stresses the importance to secure that proper compensation claim options exists for workers in cases of occupational cancer; calls on Member States to fully implement the Commission recommendation on occupational diseases1a and to ensure that proper compensation claim options exist for workers in cases of occupational cancer, securing every worker a chance to be properly compensated when having been exposed to harmful substances or affected by work-related cancer; calls on the Commission to create a European minimum list of occupational diseases with comparable recognition criteria

**Amendment**

81a. Stresses the importance to secure that proper compensation claim options exists for workers in cases of occupational cancer; calls on Member States to fully implement the Commission recommendation on occupational diseases1a and to ensure that proper compensation claim options exist for workers in cases of occupational cancer, securing every worker a chance to be properly compensated when having been exposed to harmful substances or affected by work-related cancer; calls on the Commission to create a European minimum list of occupational diseases with comparable recognition criteria
across the EU;


Amendment 1170
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 81 a (new)

Motion for a resolution
Amendment

81a. Highlights the need to recognise the relevant and indispensable role of solidarity initiatives that, with great creativity, are achieving an important boost in raising awareness, obtaining resources for diagnosis, treatment and research of cancer, and generating a sense of hope, which is a relief for both patients and their families, and an invaluable contribution to society;

Amendment 1171
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 81 b (new)

Motion for a resolution
Amendment

81b. Highlights the importance of testimony by cancer patients and survivors, whose suffering represents, for society as a whole, a model of overcoming and accepting life's setbacks, generating hope and motivation to follow their
Amendment 1172
Michèle Rivasi

Motion for a resolution
Paragraph 82

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; recalls the recommendations and tools developed by the CHRODIS+ Joint Action to foster patients’ retention at work, return to work and reintegration into the labour market; encourages the Commission to support their implementation across the Member States; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; calls for information on recurrence of cancer to be an integral part of cancer registries;

Amendment 1173
Alexis Georgoulis

Motion for a resolution
Paragraph 82

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to
facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; faciltiates the return to school of paediatric cancer survivors; recalls the recommendations and tools developed by the CHRODIS+ Joint Action to foster patients' retention at work, return to work and reintegration into the labour market; and encourages the European Commission to support their implementation across Europe advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; recommends the improvement of cancer registry information across Europe on recurrence of cancer;

Amendment 1174
Bartosz Arłukowicz

Motion for a resolution
Paragraph 82

Motion for a resolution

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

Amendment

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; calls on the Member States to support the reintegration of people with cancer into the labour market and to facilitate the balancing of work with treatment and rehabilitation needs; calls for support for employers who employ people who have had or who currently have cancer;
Amendment 1175
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Špyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 82

Motion for a resolution

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

Amendment

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; calls on the Member States to support the re-entry of cancer patients to the labour market and to facilitate the sharing of work and rehabilitation process;

Or. en

Amendment 1176
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 82

Motion for a resolution

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

Amendment

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market, also helping them in the transition to a new professional role in case of sequelae preventing their continuity in the same job, and to facilitate the return to school of paediatric cancer
Motion for a resolution
Paragraph 82

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood.
recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood;

Amendment 1179
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 82

Motion for a resolution
Amendment

82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

Amendment 1180
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 82

Motion for a resolution
Amendment

82. Calls on the Member States to improve the reintegration of cancer
survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation;

Amendment 1181
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 83

83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges;
Amendment 1182
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 83

83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges;
cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges; already calls on the Member States to raise awareness among employers;

Or. fr